ArticleThe oncologist2013

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Louis P Garrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.